Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free INTS Stock Alerts

Intensity Therapeutics (INTS) Competitors

Intensity Therapeutics logo
$4.25 -0.02 (-0.47%)
As of 08/28/2026 04:00 PM Eastern
Compare

INTS vs. SCLX, CLNN, INCR, SCYX, and GRCE

Should you buy Intensity Therapeutics stock or one of its competitors? Intensity Therapeutics's main competitors and comparable companies include Scilex (SCLX), Clene (CLNN), InterCure (INCR), SCYNEXIS (SCYX), and Grace Therapeutics (GRCE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Intensity Therapeutics compare to Scilex?

Scilex (NASDAQ:SCLX) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Intensity Therapeutics has lower revenue, but higher earnings than Scilex. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$30.25M1.52-$358.73M-$49.70N/A
Intensity TherapeuticsN/AN/A-$11.61M-$3.57N/A

Scilex has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market.

Intensity Therapeutics has a consensus target price of $7.00, indicating a potential upside of 64.71%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Intensity Therapeutics is more favorable than Scilex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Intensity Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, Scilex had 2 more articles in the media than Intensity Therapeutics. MarketBeat recorded 3 mentions for Scilex and 1 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.93 beat Scilex's score of 0.51 indicating that Intensity Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Scilex Positive
Intensity Therapeutics Positive

69.7% of Scilex shares are owned by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 7.6% of Intensity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Intensity Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scilex-1,414.57% N/A -147.00%
Intensity Therapeutics N/A -116.61%-94.01%

Summary

Intensity Therapeutics beats Scilex on 11 of the 16 factors compared between the two stocks.

How does Intensity Therapeutics compare to Clene?

Intensity Therapeutics (NASDAQ:INTS) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Intensity Therapeutics has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market. Comparatively, Clene has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Intensity Therapeutics has higher earnings, but lower revenue than Clene. Clene is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intensity TherapeuticsN/AN/A-$11.61M-$3.57N/A
Clene$200K271.78-$26.17M-$3.50N/A

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Intensity Therapeutics and Intensity Therapeutics both had 1 articles in the media. Clene's average media sentiment score of 1.89 beat Intensity Therapeutics' score of 0.93 indicating that Clene is being referred to more favorably in the news media.

Company Overall Sentiment
Intensity Therapeutics Positive
Clene Very Positive

Intensity Therapeutics has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intensity TherapeuticsN/A -116.61% -94.01%
Clene -20,063.96%N/A -137.04%

Intensity Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 64.71%. Clene has a consensus price target of $33.25, indicating a potential upside of 686.05%. Given Clene's higher possible upside, analysts clearly believe Clene is more favorable than Intensity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intensity Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Clene
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Summary

Clene beats Intensity Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Intensity Therapeutics compare to InterCure?

InterCure (NASDAQ:INCR) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Intensity Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 64.71%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Intensity Therapeutics is more favorable than InterCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InterCure
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Intensity Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

InterCure has higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterCure$78.47M0.81-$10.37M$0.03192.67
Intensity TherapeuticsN/AN/A-$11.61M-$3.57N/A

In the previous week, InterCure had 5 more articles in the media than Intensity Therapeutics. MarketBeat recorded 6 mentions for InterCure and 1 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.93 beat InterCure's score of 0.23 indicating that Intensity Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
InterCure Neutral
Intensity Therapeutics Positive

8.3% of InterCure shares are owned by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 7.6% of Intensity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

InterCure has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

InterCure's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
InterCureN/A N/A N/A
Intensity Therapeutics N/A -116.61%-94.01%

Summary

InterCure beats Intensity Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Intensity Therapeutics compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Intensity Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Intensity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SCYNEXIS-41.79% -44.15% -32.61%
Intensity Therapeutics N/A -116.61%-94.01%

SCYNEXIS currently has a consensus price target of $33.00, suggesting a potential upside of 512.24%. Intensity Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 64.71%. Given SCYNEXIS's higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Intensity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Intensity Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

SCYNEXIS has higher revenue and earnings than Intensity Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SCYNEXIS$20.60M2.60-$8.61M-$2.09N/A
Intensity TherapeuticsN/AN/A-$11.61M-$3.57N/A

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by company insiders. Comparatively, 7.6% of Intensity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SCYNEXIS has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market.

In the previous week, SCYNEXIS had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 2 mentions for SCYNEXIS and 1 mentions for Intensity Therapeutics. SCYNEXIS's average media sentiment score of 0.93 equaled Intensity Therapeutics'average media sentiment score.

Company Overall Sentiment
SCYNEXIS Positive
Intensity Therapeutics Positive

Summary

SCYNEXIS beats Intensity Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Intensity Therapeutics compare to Grace Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Intensity Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 64.71%. Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 183.02%. Given Grace Therapeutics' higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Intensity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intensity Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Grace Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Intensity Therapeutics and Intensity Therapeutics both had 1 articles in the media. Grace Therapeutics' average media sentiment score of 1.91 beat Intensity Therapeutics' score of 0.93 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Intensity Therapeutics Positive
Grace Therapeutics Very Positive

Intensity Therapeutics has a beta of 2.76, suggesting that its stock price is 176% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Grace Therapeutics' return on equity of -36.11% beat Intensity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intensity TherapeuticsN/A -116.61% -94.01%
Grace Therapeutics N/A -36.11%-34.39%

Grace Therapeutics is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intensity TherapeuticsN/AN/A-$11.61M-$3.57N/A
Grace TherapeuticsN/AN/A-$7.79M-$1.18N/A

Summary

Grace Therapeutics beats Intensity Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Intensity Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INTS vs. The Competition

Export
MetricIntensity TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$13.88M$12.15B$7.20B$12.91B
Dividend YieldN/A2.62%2.54%11.28%
P/E Ratio-1.19787.65273.1625.45
Price / SalesN/A795.07634.1994.29
Price / CashN/A91.9576.7453.00
Price / Book1.5111.9712.986.14
Net Income-$11.61M$2.83B$3.48B$348.86M
7 Day Performance-12.55%0.39%0.13%-0.80%
1 Month Performance4.94%5.34%7.08%4.13%
1 Year Performance-39.29%6.05%24.67%15.17%

Intensity Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INTS
Intensity Therapeutics
2.7952 of 5 stars		$4.25
-0.5%		$7.00
+64.7%		-39.3%$13.88MN/AN/A2,021
SCLX
Scilex
0.8751 of 5 stars		$5.65
-10.9%		N/A-69.4%$53.85M$30.25MN/A80
CLNN
Clene
2.7292 of 5 stars		$4.19
+2.4%		$33.25
+693.6%		-20.5%$52.55M$200KN/A100
INCR
InterCure
0.6487 of 5 stars		$0.93
-2.1%		N/A-27.8%$51.95M$78.47MN/A350
SCYX
SCYNEXIS
3.4684 of 5 stars		$5.15
+0.2%		$33.00
+540.8%		-19.0%$51.14M$20.60MN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:INTS) was last updated on 8/30/2026 by MarketBeat.com Staff.
From Our Partners
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...
Paradigm Press | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel
Buy this stock today
Most tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...
Chaikin Analytics | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...
Eagle Publishing | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel